IN THE SPOTLIGHT

Dr Sands on the Evolving Role of ADCs in SCLC Management

Dr Sands on the Evolving Role of ADCs in SCLC Management

Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research

Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research

Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes

Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes

FDA approves drug for persistently deadly form of lung cancer

FDA approves drug for persistently deadly form of lung cancer

IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo

IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo

ASCO: AstraZeneca's Tagrisso, Imfinzi break new grounds in lung cancer—with one standing ovation

ASCO: AstraZeneca's Tagrisso, Imfinzi break new grounds in lung cancer—with one standing ovation

FDA approves Imdelltra for patients with extensive-stage small cell lung cancer

FDA approves Imdelltra for patients with extensive-stage small cell lung cancer

Amgen Drug for Aggressive Type of Lung Cancer Wins Accelerated FDA Approval

Amgen Drug for Aggressive Type of Lung Cancer Wins Accelerated FDA Approval

FDA approves Amgen T-cell engager for small cell lung cancer

FDA approves Amgen T-cell engager for small cell lung cancer